Restoration of the ER stress response protein TDAG51 in hepatocytes mitigates NAFLD in mice.

J Biol Chem

Division of Nephrology, Department of Medicine, The Research Institute of St. Joe's Hamilton and the Hamilton Centre for Kidney Research, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada. Electronic address:

Published: February 2024

AI Article Synopsis

  • Endoplasmic reticulum stress contributes to insulin resistance and nonalcoholic fatty liver disease (NAFLD), with mice lacking the TDAG51 gene showing worsened obesity and liver issues on a high-fat diet.
  • Research found that TDAG51 protein levels are lower in various liver disease models and human liver biopsies compared to healthy controls.
  • Restoring TDAG51 in the liver through a specific virus improved insulin sensitivity and reduced fat in the liver, suggesting that maintaining TDAG51 levels could be a potential treatment for obesity and insulin resistance linked to NAFLD.

Article Abstract

Endoplasmic reticulum stress is associated with insulin resistance and the development of nonalcoholic fatty liver disease. Deficiency of the endoplasmic reticulum stress response T-cell death-associated gene 51 (TDAG51) (TDAG51) in mice promotes the development of high-fat diet (HFD)-induced obesity, fatty liver, and hepatic insulin resistance. However, whether this effect is due specifically to hepatic TDAG51 deficiency is unknown. Here, we report that hepatic TDAG51 protein levels are consistently reduced in multiple mouse models of liver steatosis and injury as well as in liver biopsies from patients with liver disease compared to normal controls. Delivery of a liver-specific adeno-associated virus (AAV) increased hepatic expression of a TDAG51-GFP fusion protein in WT, TDAG51, and leptin-deficient (ob/ob) mice. Restoration of hepatic TDAG51 protein was sufficient to increase insulin sensitivity while reducing body weight and fatty liver in HFD fed TDAG51 mice and in ob/ob mice. TDAG51 mice expressing ectopic TDAG51 display improved Akt (Ser473) phosphorylation, post-insulin stimulation. HFD-fed TDAG51 mice treated with AAV-TDAG51-GFP displayed reduced lipogenic gene expression, increased beta-oxidation and lowered hepatic and serum triglycerides, findings consistent with reduced liver weight. Further, AAV-TDAG51-GFP-treated TDAG51 mice exhibited reduced hepatic precursor and cleaved sterol regulatory-element binding proteins (SREBP-1 and SREBP-2). In vitro studies confirmed the lipid-lowering effect of TDAG51 overexpression in oleic acid-treated Huh7 cells. These studies suggest that maintaining hepatic TDAG51 protein levels represents a viable therapeutic approach for the treatment of obesity and insulin resistance associated with nonalcoholic fatty liver disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875272PMC
http://dx.doi.org/10.1016/j.jbc.2024.105655DOI Listing

Publication Analysis

Top Keywords

tdag51 mice
20
fatty liver
16
hepatic tdag51
16
tdag51
14
insulin resistance
12
liver disease
12
tdag51 protein
12
stress response
8
protein tdag51
8
mice
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!